Teva- Pharmaceutical Industries Ltd
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.
Current Price
$35.73
-0.78%GoodMoat Value
$21.98
38.5% overvaluedProfile
Valuation (TTM)
Market Cap$41.08B
P/E26.27
EV—
P/B5.19
Shares Out1.15B
P/Sales2.37
Revenue$17.35B
EV/EBITDA16.43
Teva- Pharmaceutical Industries Ltd (TEVA) Stock Analysis
Market Cap$41.08B
Current Price$35.73
P/E Ratio26.27
Forward P/E—
PEG Ratio0.38
EPS$1.21
Book Value$6.88
P/B Ratio5.19
TEVA Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 31.4% FCF growth (CAGR)
Cash vs Debt
Net Debt: 13.5B
Revenue
16.9B
FY19
16.7B
FY20
15.9B
FY21
14.9B
FY22
15.8B
FY23
16.5B
FY24
17.3B
FY25
Net Income
—
FY19
—
FY20
417M
FY21
—
FY22
—
FY23
—
FY24
1.4B
FY25
TEVA 52-Week Range
$15.38
$36.34
50-Day MA: $31.45200-Day MA: $26.37
Did you know?
Free cash flow has been growing at 31.4% annually.
Teva- Pharmaceutical Industries Ltd (TEVA) Financial Summary
Teva- Pharmaceutical Industries Ltd (TEVA) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NYSE. The stock currently trades at $35.73 with a market capitalization of $41.08B.
Key valuation metrics include a P/E ratio of 26.27, price-to-book ratio of 5.19, and EPS of $1.21. The company reports a profit margin of 9.0% and return on equity of 19.8%.
TEVA Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $41.08B |
| P/E Ratio | 26.27 |
| EPS | $1.21 |
| P/B Ratio | 5.19 |
| P/S Ratio | 2.37 |
| EV/EBITDA | 16.43 |
| Profit Margin | 9.0% |
| Return on Equity | 19.8% |
| Debt/Equity | 2.16 |
TEVA Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $16.89B | $-999.00M |
| FY20 | $16.66B | $-3.99B |
| FY21 | $15.88B | $417.00M |
| FY22 | $14.93B | $-2.45B |
| FY23 | $15.85B | $-559.00M |
| FY24 | $16.54B | $-1.64B |
| FY25 | $17.26B | $1.41B |
Teva- Pharmaceutical Industries Ltd (TEVA) Valuation
Based on GoodMoat's DCF model, Teva- Pharmaceutical Industries Ltd has a fair value estimate of $21.98. At the current price of $35.73, the stock appears 62.6% overvalued relative to our intrinsic value estimate.
TEVA Quality Indicators
Teva- Pharmaceutical Industries Ltd maintains a profit margin of 9.0% and an operating margin of 12.6%. Return on equity stands at 19.8%. The current ratio is 1.04. Debt-to-equity ratio is 2.16.
About Teva- Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.
TEVA Free Cash Flow
Teva- Pharmaceutical Industries Ltd generated $1.15B in trailing twelve-month free cash flow, representing an FCF yield of 2.79%. This moderate FCF yield indicates reasonable cash generation.
TEVA Shares Outstanding
Teva- Pharmaceutical Industries Ltd has 1.15 billion shares outstanding at a share price of $35.73, giving it a market capitalization of $41.08B.